Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Fusidic acid anhydrous
Leo Laboratories Limited
J01XC; J01XC01
Fusidic acid anhydrous
250 mg/5ml
Oral suspension
Product subject to prescription which may not be renewed (A)
Steroid antibacterials; fusidic acid
Not marketed
1977-04-01
140 mm 420 mm 75 mm 20 mm 4 m m INS022-00 WHAT IS IN THIS LEAFLET 1.What Fucidin ® Suspension is and what it is used for 2.What you need to know before you take Fucidin ® Suspension 3.How to take Fucidin ® Suspension 4.Possible side effects 5.How to store Fucidin ® Suspension 6.Contents of the pack and other information 1. WHAT FUCIDIN ® SUSPENSION IS AND WHAT IT IS USED FOR Fucidin Suspension contains fusidic acid. It is a type of antibiotic. Fucidin Suspension works by killing germs (bacteria) that cause infections. Fucidin Suspension is used to treat infections such as those caused by a bacteria called Staphylococcus. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FUCIDIN ® SUSPENSION DO NOT TAKE FUCIDIN SUSPENSION: • If you are allergic to fusidic acid or any of the other ingredients in this medicine (listed in section 6). • If you are taking statins, medicines to lower blood cholesterol. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Fucidin Suspension if: • You are taking statins (medicines to lower blood cholesterol). • You have problems with your liver or if you have recently been jaundiced (skin and whites of eyes appear yellow). • You have a blockage or a problem with your bile duct, e.g. gallstones. • You are taking some medicines called HIV-Protease Inhibitors used to treat the HIV virus. When you are taking Fucidin Suspension your doctor may take regular blood tests if you are taking other medicines which affect the liver. If you are concerned that your treatment is not as effective as it should be, tell your doctor. As with any antibiotic treatment, long term or repeated use may increase the risk of developing antibiotic resistance. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product. A few cases have been reported of severe skin reactions, which may develop into potentially life-threatening skin reactions if they are not treated. Contact your doctor immediately if you experience Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fucidin 250mg/5ml Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Fusidic acid. Each 5 ml of suspension contains 250 mg of anhydrous fusidic acid (as hemihydrate). Excipients with known effect Glucose liquid 250 mg/1 ml suspension Sorbitol (E420) 100 mg/1 ml suspension Sodium 1.6 mg/1 ml suspension Orange dry flavour (containing sucrose) 400 mcg/1 ml suspension. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension Cream coloured suspension with odour of banana. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of systemic infections due to micro-organisms sensitive to this anti-infective, such as Staphylococci. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adult dose: The usual total daily dose is 1500-2000 mg (30 – 40 ml) each day in 3 equally divided doses. _Paediatric population_ Children: The usual daily dose is 20-50 mg/kg (0.4 ml/kg – 1 ml/kg) each day in 3 equally divided doses. Method of administration For oral administration. The suspension should be shaken well before use. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients. Concomitant treatment with statins (HMG-CoA reductase inhibitors). (See section 4.4, 4.5). 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE This medicinal product contains 1.6 mg sodium per ml suspension. To be taken into consideration by patients on a controlled sodium diet. Statins (HMG-CoA reductase inhibitors) and systemic Fucidin must not be co-administered, (see section 4.3). There have been reports of rhabdomyolysis (including fatalities) in patients receiving this combination. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document